Penumbra (PEN) Cash & Equivalents Growth (3y) (2017 - 2026)
Penumbra (PEN) Cash & Equivalents Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 32.23% |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | 21.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60% |
| Mar 31, 2026 | 36.59% |
| Dec 31, 2025 | 38.82% |
| Sep 30, 2025 | 80.22% |
| Jun 30, 2025 | 93.48% |
| Mar 31, 2025 | 76.70% |
| Dec 31, 2024 | 76.12% |
| Sep 30, 2024 | 61.74% |
| Mar 31, 2024 | 58.88% |
| Dec 31, 2023 | 33.96% |
| Sep 30, 2023 | 7.94% |
| Jun 30, 2023 | -5.29% |
| Mar 31, 2023 | 9.33% |
| Dec 31, 2022 | -1.36% |
| Sep 30, 2022 | -21.08% |
| Jun 30, 2022 | -8.99% |
| Mar 31, 2022 | 0.15% |
| Dec 31, 2021 | -4.35% |
| Sep 30, 2021 | 11.56% |
| Mar 31, 2021 | 3.19% |